Yahoo Malaysia Web Search

Sign In

Search results

  1. en.wikipedia.org › wiki › Juno_TherapeuticsJuno Therapeutics - Wikipedia

    Juno Therapeutics Inc was an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute.

  2. Videos

    View all

  3. www.geekwire.com › 2022 › junos-lasting-legacy-how-Juno's lasting legacy: How the cell therapy juggernaut influenced...

    Feb 8, 2022 · Juno was a pioneer in cell therapy for cancer, selling for $9 billion in 2018. Learn how its founders, investors, and spinoffs influenced the region and the industry.

  4. www.linkedin.com › company › juno-therapeuticsJuno Therapeutics, Inc. | LinkedIn

    Juno Therapeutics, Inc. | 27,610 followers on LinkedIn. We have merged with Bristol Myers Squibb creating a leading biopharma company, ideally positioned to discover, develop and deliver...

  5. www.crunchbase.com › organization › juno-therapeuticsJuno Therapeutics - Crunchbase Company Profile & Funding

    Juno Therapeutics is a biotech company that develops immunotherapies for cancer. It was founded in 2013 and acquired by Celgene for $9B in 2018. See its funding, investors, contacts, and competitors on Crunchbase.

  6. www.fiercebiotech.com › biotech › celgene-confirms-9bn-junoCelgene confirms $9B Juno buyout, sees $3B sales for JCAR017

    Jan 22, 2018 · Celgene acquires Juno, a CAR-T specialist, to boost its hematology pipeline and growth beyond 2020. Juno's lead candidate JCAR017, in phase 1 for non-Hodgkin's lymphoma, could generate $3B in sales if approved.

  7. www.fda.gov › drugs › resources-information-approved-drugsFDA approves lisocabtagene maraleucel for relapsed or refractory...

    May 30, 2024 · On May 30, 2024, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adult patients with relapsed or refractory mantle cell lymphoma (MCL)...

  8. www.celgene.com › newsroom › cellular-immunotherapiesCelgene Corporation to Acquire Juno Therapeutics, Inc.

    Jan 22, 2018 · Celgene and Juno announced a merger agreement in January 2018, with Celgene paying $87 per share in cash for Juno. Juno is a leader in CAR T and TCR therapy development, with a pipeline of cellular immunotherapy assets for hematologic malignancies and solid tumors.